T1	intervention 23 28	CT-P6
T3	eligibility 61 94	HER2-positive early breast cancer
T4	intervention-participants 612 615	271
T5	control-participants 620 623	278
T6	outcome 679 682	pCR
T7	outcome 687 703	breast pCR rates
T8	outcome 862 914	study drug-related treatment-emergent adverse events
T9	iv-bin-percent 800 805	47.6%
T10	cv-bin-percent 818 823	52.2%
T11	outcome 956 969	heart failure
T12	iv-bin-abs 978 980	10
T13	cv-bin-abs 995 996	7
T14	outcome 1040 1071	discontinued adjuvant treatment
T15	iv-bin-abs 999 1002	Two
T16	cv-bin-abs 1013 1018	three
T2	control 36 57	reference trastuzumab
